Bleichroeder L.P. – A “new” hedge fund with old roots, has $2.8B in AUM, and already has some big winners.

0
2590
Gerson von Bleichröder (22 December 1822 – 18 February 1893) Source: Wikipedia

In the mid-19th century, Gerson von Bleichröder gained fame as the financial advisor to Otto von Bismarck, the Chancellor of the German Empire. The investment firm S. Bleichröder merged with Arhnold Bros. in 1964, eventually becoming New-York City-based Arnhold and S. Bleichroeder, Inc. That firm was renamed First Eagle Investment Management(FEIM), an investment firm that today manages $101 billion. Bleichroeder L.P. is a spin-off from FEIS. And based on early returns, the hedge fund may be a good one to follow.

From a recent regulatory filing:

On September 1, 2019, the family office personnel of FEIM, including Messrs. Michael M. Kellen and Andrew Gundlach, separated their investment management business from that of FEIM, transferring their family’s advisory client accounts, including the securities of the Company which were formerly controlled by FEIM, to the newly formed U.S. registered advisory firm named Bleichroeder LP. 

 
Because Bleichroeder L.P. now controls the former FEIS family office portfolio, a number of 13Gs and 13Ds were filed by the new firm in early Sept.– predominately small and micro-cap medical and tech stocks. The performance of these stocks since Sept. 1 are shown below.

Bleichroeder L.P. 13D & 13G filings since the hedge fund’s registration become effective on Sept.1, 2019.

Filing DateFormSymbol9-1-19 Price2-7-20 Price% Chg% ownership
1/9/20SC 13G/AARQL2.28%
9/27/19SC 13G/ADUOT17.75%
9/13/19SC 13GSAVA1.228.16569%13.59%
9/6/19SC 13G/AARQL13.25%
9/6/19SC 13GDRRX1.781.59-11%13.79%
9/6/19SC 13GIVAC21.64%
9/6/19SC 13GDUOT5.67.515.73%
9/6/19SC 13GCUI0.671.164%12.90%
9/5/19SC 13GARQL9.1120120%13.25%
9/5/19SC 13GIDN4.78.9190%17.24%
9/5/19SC 13GIVAC4.866.636%21.64%
9/5/19SC 13GINVE4.985.041%11.24%
9/5/19SC 13GARCW0.160.19321%9.23%
9/5/19SC 13DARDMQ0.1550.1499-3%26.54%

Bleichroeder L.P is managed by Andrew Gundlach and Michael Kellen. Gundlach is a director of First Eagle Investment Management (FEIM), a New York-based, value-oriented investment management firm that primarily manages the First Eagle Funds. He joined FEIM in 2006 and is a member of the firm’s founding family. Gundlach received BS and MS degrees from Georgetown University’s School of Foreign Service. Michael Kellen has been a Vice Chairman & Director at FEIM since October-2003.

It’s apparent by the holdings disclosed above, that Bleichroeder L.P. will have a small-cap focus. Indeed, in the firm’s ADV part II filed with the SEC, the firm makes the following disclosure.

Small Capitalization Stocks


At any given time, Bleichroeder may make significant investments in smaller-sized companies of a less seasoned nature whose securities may be traded in the over-the-counter market. These “secondary” securities often involve significantly greater risks than the securities of larger, better known companies. In addition to being subject to the general market risk that common stock prices may decline over short or even extended periods, Bleichroeder may invest in securities of companies that are not well known to the investing public, may not have significant institutional ownership and may have cyclical, static or only moderate growth prospects. The stocks of such companies may be more volatile in price and have lower trading volumes than the larger capitalization stocks.

The focus on small cap has paid off so far. Bleichroeder L.P showed a 13.59% stake in Cassava Sciences Inc (SAVA) on Sept 13. From Dec.19 through Jan. 3, the stock skyrocketed 479% as the company presented a drug candidate for Alzheimer’s disease at an investment conference. SAVA also showed heavy insider buying.

Chart source: Interactive Brokers

Another Bleichroeder holding, ArQule, Inc. (ARQL), was bought-out by Merck (MRK) for $2.7 billion ($20/share cash). ArQule is a precision-focused biotech targeting indications with high unmet medical need. That was a 120% gain for the hedge fund, based on the Sept. 9 filing price.

In recent days, Bleichroeder L.P. has added to the following positions in companies it has 10%+ stakes in. The holdings increases were disclosed in Form 4 filings.

Bleichroeder L.P. recently added to 10%+ stakes in Durect Corp. (DRRX) and Identiv Inc. (INVE).

Form4 DateCompanyTickerTransactionTrade Date Shares Avg. Price Total 
06-Feb-2020Durect Corp.DRRXMarket Purchase06-Feb-2020         75,000 1.65 $ 123,622
06-Feb-2020Durect Corp.DRRXMarket Purchase05-Feb-2020         74,998 1.69 $ 126,777
05-Feb-2020Identiv Inc.INVEMarket Purchase05-Feb-2020         10,113 4.9 $   49,554
06-Feb-2020Durect Corp.DRRXMarket Purchase04-Feb-2020         77,500 1.7 $ 131,510
05-Feb-2020Identiv Inc.INVEMarket Purchase04-Feb-2020         21,333 4.93 $ 105,136
05-Feb-2020Identiv Inc.INVEMarket Purchase03-Feb-2020       146,889 4.9 $ 719,776

Identiv Inc (INVE), with an $86 million market cap, is a provider of identity credentials and secure access solutions. After touching a high of $7.03 in Jan., INVE reported preliminary fiscal year 2019 results on Jan. 31 which disappointed investors, sending the stock to eight month lows. Bleichroeder added shares at around $4.9 on Feb 3-5.

After touching a high of $3.95 on Dec. 31, Durect Corp. (DRRX) skidded all the way to $1.57 on Feb. 6. A split FDA vote on bupivacaine — an extended-release solution for post-surgical analgesia — put pressure on the shares. Bleichroeder bought more at $1.65 – $1.70 on Feb. 4 – 6.

Bleichroeder L.P. will file a 13F by Feb. 15, allowing investors to get a detailed look at the hedge fund’s long portfolio.

Contact Mark about investing based on SEC filings and smart money disclosures.

Disclaimer:

This investment blog (the “Blog”) is created and authored by Mark W. Gaffney (the “Content Creator”) and is published and provided for informational and entertainment purposes only (collectively, the “Blog Service”). The information in the Blog constitutes the Content Creator’s own opinions. None of the information contained in the Blog constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You understand that the Content Creator is not advising, and will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in the Blog may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

From time to time, the Content Creator or its affiliates may hold positions or other interests in securities mentioned in the Blog and may trade for their own account(s) based on the information presented. The Content Creator may also take positions inconsistent with the views expressed in its messages on the Blog.

The Content Creator may hold licenses with FINRA, the SEC or states securities authorities and these licenses may or may not be disclosed by the Content Creator in the Blog.

Investing in the investments discussed in the Blog may be risky and speculative. The companies may have limited operating histories, little available public information, and the stocks they issue may be volatile and illiquid. Trading in such securities can result in immediate and substantial losses of the capital invested. You should use invest risk capital, and not capital required for other purposes, such as retirement savings, student loans, mortgages or education.

Full Disclaimer.